{"transactions":[{"id":4623725,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-21T22:21:29.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":1279,"price":69.5696,"value":88979.5184,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":495686,"source":{"system":"sec-edgar","filing":"0001470831-26-000897","document":"wk-form4_1790029286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000897/wk-form4_1790029286.xml","form_type":"4"}},{"id":4623724,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-21T22:21:29.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":8721,"price":69.0136,"value":601867.6056,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":496965,"source":{"system":"sec-edgar","filing":"0001470831-26-000897","document":"wk-form4_1790029286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000897/wk-form4_1790029286.xml","form_type":"4"}},{"id":679964,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":100,"price":85.65,"value":8565.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":505686,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679963,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":84.6867,"value":152436.06,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":505786,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679962,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":8100,"price":83.8588,"value":679256.28,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":507586,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679961,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":1199,"price":83.7732,"value":100444.0668,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":243327,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679960,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":14602,"price":82.9922,"value":1211852.1044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":244526,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679959,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":17279,"price":82.2104,"value":1420513.5016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":259128,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679958,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":81.1494,"value":154183.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":276407,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":683946,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22366,"kind":"person","name":"Trimarchi Thomas","position":1,"cik":"0002030813","reported_name":"Trimarchi Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:40.000Z","date":"2026-08-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":22781,"price":79.86,"value":1819290.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":336529,"source":{"system":"sec-edgar","filing":"0001470831-26-000837","document":"wk-form4_1787090557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030813/000147083126000837/wk-form4_1787090557.xml","form_type":"4"}},{"id":683607,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":6520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":91274,"derivative":{"underlying":"Common Stock","underlying_shares":6520},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683606,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":11554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":115538,"derivative":{"underlying":"Common Stock","underlying_shares":11554},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683605,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":19599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":117596,"derivative":{"underlying":"Common Stock","underlying_shares":19599},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683604,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":33544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":67088,"derivative":{"underlying":"Common Stock","underlying_shares":33544},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683603,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":36237,"price":79.86,"value":2893886.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":278307,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683602,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":6520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":314544,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683601,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":11554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":308024,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683600,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":19599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":296470,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683599,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":33544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":276871,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":684014,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22387,"kind":"person","name":"Apuli Maricel","position":1,"cik":"0002058197","reported_name":"Apuli Maricel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:24.000Z","date":"2026-08-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":4714,"price":79.86,"value":376460.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":122687,"source":{"system":"sec-edgar","filing":"0001470831-26-000835","document":"wk-form4_1787090542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2058197/000147083126000835/wk-form4_1787090542.xml","form_type":"4"}},{"id":699096,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22387,"kind":"person","name":"Apuli Maricel","position":1,"cik":"0002058197","reported_name":"Apuli Maricel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-03T20:20:53.000Z","date":"2026-07-30","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":80.06,"value":160120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025."}],"balance_after":127401,"source":{"system":"sec-edgar","filing":"0001470831-26-000745","document":"wk-form4_1785788451.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2058197/000147083126000745/wk-form4_1785788451.xml","form_type":"4"}},{"id":710877,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":30882,"kind":"person","name":"Ellis Andrea","position":1,"cik":"0001877680","reported_name":"Ellis Andrea","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2026-07-13T20:41:33.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":17167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":17167,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17167},"source":{"system":"sec-edgar","filing":"0001470831-26-000709","document":"wk-form4_1783975290.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1877680/000147083126000709/wk-form4_1783975290.xml","form_type":"4"}},{"id":710876,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":30882,"kind":"person","name":"Ellis Andrea","position":1,"cik":"0001877680","reported_name":"Ellis Andrea","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:41:33.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":17167,"price":84,"value":1442028.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025."}],"balance_after":22579,"source":{"system":"sec-edgar","filing":"0001470831-26-000709","document":"wk-form4_1783975290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877680/000147083126000709/wk-form4_1783975290.xml","form_type":"4"}},{"id":710875,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":30882,"kind":"person","name":"Ellis Andrea","position":1,"cik":"0001877680","reported_name":"Ellis Andrea","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:41:33.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":17167,"price":16.75,"value":287547.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025."}],"balance_after":39746,"source":{"system":"sec-edgar","filing":"0001470831-26-000709","document":"wk-form4_1783975290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877680/000147083126000709/wk-form4_1783975290.xml","form_type":"4"}},{"id":710627,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":17167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":0,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17167},"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710626,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":112422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":0,"derivative":{"exercise_price":29,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":112422},"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710625,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":0,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710624,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":112422,"price":90,"value":10117980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":8383,"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710623,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":36167,"price":84,"value":3038028.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":120805,"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710622,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":17167,"price":16.75,"value":287547.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":156972,"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710621,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":112422,"price":29,"value":3260238.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":139805,"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":710620,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:40:35.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":19000,"price":8.45,"value":160550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":27383,"source":{"system":"sec-edgar","filing":"0001470831-26-000708","document":"wk-form4_1783975232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000708/wk-form4_1783975232.xml","form_type":"4"}},{"id":727733,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":17167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":17167,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17167},"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727732,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727731,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-22","kind":"grant","planned":true,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727730,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":37167,"price":70,"value":2601690.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":8383,"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727729,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":true,"shares":17167,"price":16.75,"value":287547.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":45550,"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727728,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":8.45,"value":169000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":28383,"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727727,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":2196,"price":68.57,"value":150579.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":8383,"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727726,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:29.000Z","date":"2026-06-22","kind":"grant","planned":true,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10579,"source":{"system":"sec-edgar","filing":"0001470831-26-000636","document":"wk-form4_1782338786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000636/wk-form4_1782338786.xml","form_type":"4"}},{"id":727802,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":2808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":5617,"derivative":{"exercise_price":41.73,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":2808},"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727801,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-22","kind":"grant","planned":true,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727800,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":2196,"price":68.57,"value":150579.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025."}],"balance_after":9259,"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727799,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":2808,"price":68,"value":190944.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025."}],"balance_after":11455,"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727798,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":2808,"price":41.73,"value":117177.84,"ownership":{"direct":true},"balance_after":14263,"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727797,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29779,"kind":"person","name":"Valantine Hannah","position":1,"cik":"0001855608","reported_name":"Valantine Hannah","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:22.000Z","date":"2026-06-22","kind":"grant","planned":true,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":11455,"source":{"system":"sec-edgar","filing":"0001470831-26-000635","document":"wk-form4_1782338780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855608/000147083126000635/wk-form4_1782338780.xml","form_type":"4"}},{"id":727725,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:17.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000634","document":"wk-form4_1782338774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000634/wk-form4_1782338774.xml","form_type":"4"}},{"id":727724,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:17.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":18079,"source":{"system":"sec-edgar","filing":"0001470831-26-000634","document":"wk-form4_1782338774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000634/wk-form4_1782338774.xml","form_type":"4"}},{"id":727723,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:11.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000633","document":"wk-form4_1782338768.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000633/wk-form4_1782338768.xml","form_type":"4"}},{"id":727722,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:11.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":919876,"source":{"system":"sec-edgar","filing":"0001470831-26-000633","document":"wk-form4_1782338768.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000633/wk-form4_1782338768.xml","form_type":"4"}},{"id":727721,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35665,"kind":"person","name":"AGUIAR ERIC","position":1,"cik":"0001262325","reported_name":"AGUIAR ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000632","document":"wk-form4_1782338761.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000632/wk-form4_1782338761.xml","form_type":"4"}},{"id":727720,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35665,"kind":"person","name":"AGUIAR ERIC","position":1,"cik":"0001262325","reported_name":"AGUIAR ERIC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:05.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10579,"source":{"system":"sec-edgar","filing":"0001470831-26-000632","document":"wk-form4_1782338761.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000632/wk-form4_1782338761.xml","form_type":"4"}},{"id":727988,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35764,"kind":"person","name":"DANIELS RONALD J","position":1,"cik":"0001164475","reported_name":"DANIELS RONALD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:58.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000631","document":"wk-form4_1782338755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164475/000147083126000631/wk-form4_1782338755.xml","form_type":"4"}},{"id":727987,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35764,"kind":"person","name":"DANIELS RONALD J","position":1,"cik":"0001164475","reported_name":"DANIELS RONALD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:58.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20981,"source":{"system":"sec-edgar","filing":"0001470831-26-000631","document":"wk-form4_1782338755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164475/000147083126000631/wk-form4_1782338755.xml","form_type":"4"}},{"id":728194,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":30882,"kind":"person","name":"Ellis Andrea","position":1,"cik":"0001877680","reported_name":"Ellis Andrea","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:52.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000630","document":"wk-form4_1782338749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1877680/000147083126000630/wk-form4_1782338749.xml","form_type":"4"}},{"id":728193,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":30882,"kind":"person","name":"Ellis Andrea","position":1,"cik":"0001877680","reported_name":"Ellis Andrea","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:52.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":22579,"source":{"system":"sec-edgar","filing":"0001470831-26-000630","document":"wk-form4_1782338749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877680/000147083126000630/wk-form4_1782338749.xml","form_type":"4"}},{"id":728021,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:45.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000629","document":"wk-form4_1782338741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000147083126000629/wk-form4_1782338741.xml","form_type":"4"}},{"id":728020,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":11868,"kind":"person","name":"Hassan Fred","position":1,"cik":"0001110744","reported_name":"Hassan Fred","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:45.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":29879,"source":{"system":"sec-edgar","filing":"0001470831-26-000629","document":"wk-form4_1782338741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110744/000147083126000629/wk-form4_1782338741.xml","form_type":"4"}},{"id":727719,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:36.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000628","document":"wk-form4_1782338732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000628/wk-form4_1782338732.xml","form_type":"4"}},{"id":727718,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:36.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the \"Trust\") were previously reported as directly owned by the Reporting Person."}],"balance_after":19070,"source":{"system":"sec-edgar","filing":"0001470831-26-000628","document":"wk-form4_1782338732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000628/wk-form4_1782338732.xml","form_type":"4"}},{"id":727717,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35664,"kind":"person","name":"MCCORMICK FRANK","position":1,"cik":"0001257809","reported_name":"MCCORMICK FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:29.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000627","document":"wk-form4_1782338726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000627/wk-form4_1782338726.xml","form_type":"4"}},{"id":727716,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35664,"kind":"person","name":"MCCORMICK FRANK","position":1,"cik":"0001257809","reported_name":"MCCORMICK FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:29.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Excludes 428,976  shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026."}],"balance_after":10579,"source":{"system":"sec-edgar","filing":"0001470831-26-000627","document":"wk-form4_1782338726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000627/wk-form4_1782338726.xml","form_type":"4"}},{"id":727715,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":32460,"kind":"person","name":"Dachille Douglas A.","position":1,"cik":"0001652908","reported_name":"Dachille Douglas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:23.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000626","document":"wk-form4_1782338719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000626/wk-form4_1782338719.xml","form_type":"4"}},{"id":727714,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":32460,"kind":"person","name":"Dachille Douglas A.","position":1,"cik":"0001652908","reported_name":"Dachille Douglas A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:23.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":10579,"source":{"system":"sec-edgar","filing":"0001470831-26-000626","document":"wk-form4_1782338719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000626/wk-form4_1782338719.xml","form_type":"4"}},{"id":727713,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35663,"kind":"person","name":"Satvat Ali J.","position":1,"cik":"0001621788","reported_name":"Satvat Ali J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:16.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000625","document":"wk-form4_1782338712.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000625/wk-form4_1782338712.xml","form_type":"4"}},{"id":727712,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35663,"kind":"person","name":"Satvat Ali J.","position":1,"cik":"0001621788","reported_name":"Satvat Ali J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:16.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":169983,"source":{"system":"sec-edgar","filing":"0001470831-26-000625","document":"wk-form4_1782338712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000625/wk-form4_1782338712.xml","form_type":"4"}},{"id":729175,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35666,"kind":"person","name":"HOMCY CHARLES J","position":1,"cik":"0001192591","reported_name":"HOMCY CHARLES J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T22:46:04.000Z","date":"2026-06-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":788,"price":66.27,"value":52220.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":915886,"source":{"system":"sec-edgar","filing":"0001470831-26-000569","document":"wk-form4_1782254762.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000569/wk-form4_1782254762.xml","form_type":"4"}},{"id":734175,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":false,"shares":17167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":34334,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":17167},"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":734174,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":false,"shares":65921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":39000,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":65921},"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":734173,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":1503,"price":67.1425,"value":100915.1775,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":6589,"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":734172,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":88737,"price":66.6153,"value":5911241.8761,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":8092,"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":734171,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":true,"shares":17167,"price":16.75,"value":287547.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":96829,"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":734170,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":861,"kind":"person","name":"Cook Jennifer E.","position":1,"cik":"0001754371","reported_name":"Cook Jennifer E.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T20:45:11.000Z","date":"2026-06-15","kind":"exercise","planned":true,"acquired":true,"shares":65921,"price":8.45,"value":557032.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026."}],"balance_after":79662,"source":{"system":"sec-edgar","filing":"0001470831-26-000550","document":"wk-form4_1781729104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000550/wk-form4_1781729104.xml","form_type":"4"}},{"id":746261,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":4415,"price":68.9593,"value":304455.3095,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4318447,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746260,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":8437,"price":67.8848,"value":572744.0576,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4322862,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746259,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7148,"price":67.199,"value":480338.452,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4331299,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746258,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":4416,"price":68.9593,"value":304524.2688,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":515686,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746257,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":8437,"price":67.8848,"value":572744.0576,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":520102,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746256,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7147,"price":67.199,"value":480271.253,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":528539,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746255,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":450,"price":68.2697,"value":30721.365,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4338447,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746254,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":15921,"price":67.7377,"value":1078451.9217,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4338897,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746253,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":1429,"price":66.723,"value":95347.167,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4354818,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746252,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":65.7202,"value":144584.44,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4356247,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746251,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":450,"price":68.2697,"value":30721.365,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":535686,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746250,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":15921,"price":67.7378,"value":1078453.5138,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":536136,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746249,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":1429,"price":66.723,"value":95347.167,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":552057,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746248,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":65.7202,"value":144584.44,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":553486,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":763869,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":800,"price":70.9189,"value":56735.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":243327,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763868,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":11250,"price":70.4814,"value":792915.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":244127,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763867,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":5072,"price":69.2235,"value":351101.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":255377,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763866,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":6725,"price":68.3025,"value":459334.3125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":260449,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763865,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":2256,"price":67.5687,"value":152434.9872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":267174,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":772615,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22366,"kind":"person","name":"Trimarchi Thomas","position":1,"cik":"0002030813","reported_name":"Trimarchi Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-19T20:30:14.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":3195,"price":65.9507,"value":210712.4865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $65.54  to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":359194,"source":{"system":"sec-edgar","filing":"0001470831-26-000473","document":"wk-form4_1779222603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2030813/000147083126000473/wk-form4_1779222603.xml","form_type":"4"}},{"id":772614,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22366,"kind":"person","name":"Trimarchi Thomas","position":1,"cik":"0002030813","reported_name":"Trimarchi Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-19T20:30:14.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":10456,"price":64.8151,"value":677706.6856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":362389,"source":{"system":"sec-edgar","filing":"0001470831-26-000473","document":"wk-form4_1779222603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2030813/000147083126000473/wk-form4_1779222603.xml","form_type":"4"}},{"id":772613,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":22366,"kind":"person","name":"Trimarchi Thomas","position":1,"cik":"0002030813","reported_name":"Trimarchi Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-19T20:30:14.000Z","date":"2026-05-16","kind":"tax_withholding","planned":true,"acquired":false,"shares":22781,"price":66.13,"value":1506507.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":372845,"source":{"system":"sec-edgar","filing":"0001470831-26-000473","document":"wk-form4_1779222603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030813/000147083126000473/wk-form4_1779222603.xml","form_type":"4"}},{"id":772167,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":6519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":97794,"derivative":{"underlying":"Common Stock","underlying_shares":6519},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772166,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":11553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":127092,"derivative":{"underlying":"Common Stock","underlying_shares":11553},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772165,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":19599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":137195,"derivative":{"underlying":"Common Stock","underlying_shares":19599},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772164,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":33544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":100632,"derivative":{"underlying":"Common Stock","underlying_shares":33544},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772163,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":36236,"price":66.13,"value":2396286.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,215 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":269430,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}}],"next_cursor":"2026-05-19T20:27:55.000000Z,772163"}